CompaniesBastion Biologics

Bastion Biologics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (7)
View all

Total Trials

7

As Lead Sponsor

6

As Collaborator

1

Total Enrollment

2,025

By Phase

PHASE1: 2PHASE3: 4PHASE2: 1

By Status

COMPLETED: 5RECRUITING: 2
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
NCT05323708
NCT05345691
NCT05335356
NCT06016387
NCT06038539
Hover over trial bars to see details

Recent Trials

NCT06738277Lead Sponsor
This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).
PHASE1Completed
186 participants
Started: Jan 9, 2025 · Completed: Jul 12, 2025
NCT06038539Lead Sponsor
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
PHASE3Recruiting
382 participants
Started: Jan 6, 2025 · Completed: Nov 15, 2026
NCT06016387Collaborator
Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD
PHASE2Recruiting
30 participants
Started: Nov 25, 2023 · Completed: Oct 5, 2028
NCT05637515Lead Sponsor
Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity
PHASE3Completed
374 participants
Started: Nov 21, 2022 · Completed: Sep 19, 2023
NCT05335356Lead Sponsor
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
PHASE3Completed
384 participants
Started: Jun 28, 2022 · Completed: Nov 15, 2023
View all 7 trials →